Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

Insilico Medicine(“Insilico”), a global leading generative artificial intelligence (AI)-driven biotechnology company, ...

SAN FRANCISCO — While generative AI (AI) is being hailed as a game-changer as it sweeps the globe, the concept of “in silico medicine,” or computational medicine, is not exactly a new one.

With its unique target discovery platforms, PandaOmics and Chemistry42, AI company Insilico is transforming the world of research and development. Deep learning in biopharma has come of age.

Insilico Medicine ("Insilico"), a clinical-stage generative AI-driven biotechnology company, has launched a preview version of its draft outline research assistant, Science42:DORA, to streamline ...

The global artificial intelligence (AI) in drug discovery market is projected to reach USD 6.89 billion by 2029 from USD 1.86 ...